Drug Maker Named In Investor Suit Over Diabetes Drug Candidate Misstatements

Mealey's (May 27, 2021, 9:59 AM EDT) -- TRENTON, N.J. — A biopharmaceutical company violated federal securities laws by publicly misrepresenting the likelihood that its Type 1 diabetes treatment drug would gain U.S. Food and Drug Administration approval, which...
To view the full article, register now.